Scholarlink

<p>This study aims to estimate the effects of vitamin D supplementation on cardiovascular diseases in populations with different baseline vitamin D distributions, by emulating the VITAL and D-Health trials within the UK Biobank. We emulated randomized trials using subcohorts of the UK Biobank selected to match the inclusion criteria of the VITAL and D-Health trials (n = 237,502 and 185,809, respectively). Exposures were defined as increases in serum 25-hydroxyvitamin-D concentrations of 30&#xa0;nmol/L and 38&#xa0;nmol/L, corresponding to the intervention effects in the trials. Outcomes included cardiovascular mortality, myocardial infarction, ischemic stroke, and major adverse cardiovascular events. Expected hazard ratios over trial median follow-up durations of 5.3 and 5.7&#xa0;years were estimated using Cox proportional hazards models. Vitamin D insufficiency was more common in the UK Biobank than in the original trials. When participants were weighted to match the trial baseline 25-hydroxyvitamin-D distributions, the expected effects became more similar to the largely null findings reported in the original trials. By contrast, among individuals with vitamin D insufficiency or deficiency, increases in 25-hydroxyvitamin-D concentration as achieved in the trials were associated with significantly lower risks of cardiovascular outcomes, except ischemic stroke. For cardiovascular mortality, hazard ratios ranged from 0.74 (95% CI 0.62–0.88) to 0.79 (95% CI 0.69–0.91) across both trial emulations. The largely null findings observed in the trials may partly reflect that the trial populations were predominantly vitamin D-replete. Our emulated trials suggest that substantial cardiovascular benefits from vitamin D supplementation may be expected among populations with low vitamin D status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of vitamin D supplementation on cardiovascular outcomes: randomized trials revisited

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Youqing Wang,
  • Sha Sha,
  • Tafirenyika Gwenzi,
  • Ben Schöttker,
  • Hermann Brenner

摘要

This study aims to estimate the effects of vitamin D supplementation on cardiovascular diseases in populations with different baseline vitamin D distributions, by emulating the VITAL and D-Health trials within the UK Biobank. We emulated randomized trials using subcohorts of the UK Biobank selected to match the inclusion criteria of the VITAL and D-Health trials (n = 237,502 and 185,809, respectively). Exposures were defined as increases in serum 25-hydroxyvitamin-D concentrations of 30 nmol/L and 38 nmol/L, corresponding to the intervention effects in the trials. Outcomes included cardiovascular mortality, myocardial infarction, ischemic stroke, and major adverse cardiovascular events. Expected hazard ratios over trial median follow-up durations of 5.3 and 5.7 years were estimated using Cox proportional hazards models. Vitamin D insufficiency was more common in the UK Biobank than in the original trials. When participants were weighted to match the trial baseline 25-hydroxyvitamin-D distributions, the expected effects became more similar to the largely null findings reported in the original trials. By contrast, among individuals with vitamin D insufficiency or deficiency, increases in 25-hydroxyvitamin-D concentration as achieved in the trials were associated with significantly lower risks of cardiovascular outcomes, except ischemic stroke. For cardiovascular mortality, hazard ratios ranged from 0.74 (95% CI 0.62–0.88) to 0.79 (95% CI 0.69–0.91) across both trial emulations. The largely null findings observed in the trials may partly reflect that the trial populations were predominantly vitamin D-replete. Our emulated trials suggest that substantial cardiovascular benefits from vitamin D supplementation may be expected among populations with low vitamin D status.